Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

EyeGate Pharma Collaborating With GSK

By R&D Editors | April 29, 2010

EyeGate Pharma, the leader in non-invasive ocular drug delivery, announces that they have established a research collaboration with GlaxoSmithKline (GSK) to evaluate the delivery of several GSK therapies to the anterior (front) and posterior (back) tissues of the eye using the EyeGate II delivery system. Specific terms of the agreement were not disclosed. 

Stephen From, President and Chief Executive Officer of EyeGate Pharma, commented, “EyeGate has developed a unique, non-invasive system that delivers therapeutics for ocular diseases. Our research collaboration with GlaxoSmithKline seeks to demonstrate the ability of EyeGate’s proprietary technology in delivering GSK molecules targeted to areas of the eye.”

Currently available ocular drug delivery options, which include topical drops and intravitreal injections, have limitations and associated risks. Ophthalmic drops are poorly absorbed into ocular tissues and can result in significant systemic concentrations. Intravitreal injections can lead to hemorrhaging, retinal detachment, endophalmitis, and other complications. To address the need for improved ocular drug delivery, EyeGate Pharma has developed a novel, non-invasive device that uses low-level electrical current to deliver drug substances to targeted areas of the eye. 

EyeGate is the first company to conduct multiple controlled clinical trials to assess the safety and efficacy of iontophoresis technology to deliver therapeutics into the eye. EyeGate has successfully completed two Phase II studies of EGP-437, a corticosteroid solution administered by the EyeGate II delivery system: one in dry eye syndrome (DES) patients and one in anterior uveitis patients.

Date: April 29, 2010
Source: EyeGate Pharma 

Related Articles Read More >

Certara’s COVID vaccine model is focus of Episode 8 of R&D 100 – The Podcast
New dangers in the woods — and the hope that research offers us
PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars